Trials / Completed
CompletedNCT00151333
Study Evaluating SRA-333 in Mild to Moderate Alzheimer's Disease (AD)
A Randomized, Double-blind, Placebo-controlled, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics Trial of Multiple Ascending Fixed Doses of SRA-333 in Subjects With Mild to Moderate Alzheimer's Disease.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 16 (planned)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 50 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
To determine the safety and tolerability of multiple ascending fixed oral doses of SRA-333 in subjects with mild to moderate Alzheimer's disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SRA-333 |
Timeline
- Start date
- 2005-02-01
- Primary completion
- 2005-04-01
- Completion
- 2005-04-01
- First posted
- 2005-09-08
- Last updated
- 2009-09-04
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00151333. Inclusion in this directory is not an endorsement.